NR 566 ADVANCED PHARMACOLOGY
MIDTERM EXAM QUESTIONS AND
VERIFIED ANSWERS | 100% CORRECT |
GRADE A+
1. A patient with chronic kidney disease is prescribed a drug that is primarily renally excreted.
What adjustment is most likely necessary to avoid toxicity?
A. Decrease the dosing interval
B. Increase the loading dose
C. Change the route to intramuscular
D. Decrease the dose or increase the dosing interval
Answer: D
Conceptual Explanation: Renal impairment reduces the clearance of drugs excreted by
the kidneys, necessitating a dose reduction or a longer interval between doses to prevent
accumulation and toxicity.
2. Which of the following describes the ‘first-pass effect’ in pharmacology?
A. The metabolism of an oral drug in the liver before it reaches systemic circulation
,B. The rapid excretion of a drug by the kidneys
C. The binding of a drug to plasma albumin in the bloodstream
D. The movement of a drug from the site of administration to the blood
Answer: A
Conceptual Explanation: The first-pass effect refers to the metabolic processing of an
orally administered drug by the liver or intestines, which significantly reduces the
concentration of the active drug before it reaches the systemic circulation.
3. A patient is taking Warfarin (Coumadin) and is started on Rifampin, a known potent
CYP450 enzyme inducer. What is the expected effect on the INR?
A. The INR will increase, increasing the risk of bleeding
B. The INR will remain stable as Rifampin does not affect Warfarin
C. The INR will decrease, increasing the risk of clots
D. The INR will fluctuate unpredictably
Answer: C
Conceptual Explanation: Rifampin induces the enzymes that metabolize Warfarin, leading
to faster breakdown of the drug, lower plasma levels, and a subsequent decrease in the INR
(International Normalized Ratio).
4. According to the FDA Pregnancy Categories, Category X drugs are defined as:
A. Studies fail to demonstrate a risk to the fetus in the first trimester
, B. Animal studies show adverse effects, but human studies are lacking
C. Studies in animals or humans have demonstrated fetal abnormalities and the risk
outweighs any benefit
D. Potential benefits may warrant use of the drug despite potential risks
Answer: C
Conceptual Explanation: Category X indicates that the drug is contraindicated in women
who are or may become pregnant because the risks of fetal harm clearly outweigh any
possible therapeutic benefit.
5. Why are infants at a higher risk for drug toxicity compared to adults?
A. Infants have a more efficient blood-brain barrier
B. Infants have immature renal and hepatic function
C. Infants have higher levels of plasma proteins for drug binding
D. Infants have lower total body water percentage
Answer: B
Conceptual Explanation: The immature state of the liver and kidneys in infants leads to
slower metabolism and excretion of drugs, significantly increasing the risk for drug
accumulation and toxicity.
MIDTERM EXAM QUESTIONS AND
VERIFIED ANSWERS | 100% CORRECT |
GRADE A+
1. A patient with chronic kidney disease is prescribed a drug that is primarily renally excreted.
What adjustment is most likely necessary to avoid toxicity?
A. Decrease the dosing interval
B. Increase the loading dose
C. Change the route to intramuscular
D. Decrease the dose or increase the dosing interval
Answer: D
Conceptual Explanation: Renal impairment reduces the clearance of drugs excreted by
the kidneys, necessitating a dose reduction or a longer interval between doses to prevent
accumulation and toxicity.
2. Which of the following describes the ‘first-pass effect’ in pharmacology?
A. The metabolism of an oral drug in the liver before it reaches systemic circulation
,B. The rapid excretion of a drug by the kidneys
C. The binding of a drug to plasma albumin in the bloodstream
D. The movement of a drug from the site of administration to the blood
Answer: A
Conceptual Explanation: The first-pass effect refers to the metabolic processing of an
orally administered drug by the liver or intestines, which significantly reduces the
concentration of the active drug before it reaches the systemic circulation.
3. A patient is taking Warfarin (Coumadin) and is started on Rifampin, a known potent
CYP450 enzyme inducer. What is the expected effect on the INR?
A. The INR will increase, increasing the risk of bleeding
B. The INR will remain stable as Rifampin does not affect Warfarin
C. The INR will decrease, increasing the risk of clots
D. The INR will fluctuate unpredictably
Answer: C
Conceptual Explanation: Rifampin induces the enzymes that metabolize Warfarin, leading
to faster breakdown of the drug, lower plasma levels, and a subsequent decrease in the INR
(International Normalized Ratio).
4. According to the FDA Pregnancy Categories, Category X drugs are defined as:
A. Studies fail to demonstrate a risk to the fetus in the first trimester
, B. Animal studies show adverse effects, but human studies are lacking
C. Studies in animals or humans have demonstrated fetal abnormalities and the risk
outweighs any benefit
D. Potential benefits may warrant use of the drug despite potential risks
Answer: C
Conceptual Explanation: Category X indicates that the drug is contraindicated in women
who are or may become pregnant because the risks of fetal harm clearly outweigh any
possible therapeutic benefit.
5. Why are infants at a higher risk for drug toxicity compared to adults?
A. Infants have a more efficient blood-brain barrier
B. Infants have immature renal and hepatic function
C. Infants have higher levels of plasma proteins for drug binding
D. Infants have lower total body water percentage
Answer: B
Conceptual Explanation: The immature state of the liver and kidneys in infants leads to
slower metabolism and excretion of drugs, significantly increasing the risk for drug
accumulation and toxicity.
